Kaya Ltd. announces an acquisition

The stated intended use is a three-way allocation, not debt reduction: 50% for clinic-related capital expenditure, 25% for working capital, and 25% for general corporate purposes. The clinic capex covers opening new clinics, renovating existing clinics, and acquiring medical equipment; working capital includes inventory and vendor payments. The proceeds were expected to be utilized by the end of FY28 ^[1].

On the specific alternatives:

• Debt reduction: No separate allocation for repayment of debt is identified in the reported objects of the issue ^[1].
• Working capital: 25% of the gross proceeds, or approximately ₹12.5 Cr out of ₹49.99 Cr, was earmarked for working capital ^[1].
• Clinic-expansion capex: 50%, or approximately ₹25.0 Cr, was earmarked for new clinics, renovation and medical equipment ^[1].
• General corporate purposes: The remaining 25% was reserved for this category ^[1].

Important filing caveat: the filing extract was also reported as establishing the amount raised without providing a confirmed, filing-level split between debt repayment, working capital and capex ^[2]. Accordingly, the 50%/25%/25% allocation should be treated as the company’s reported intended-use summary, while the cited material does not support saying that any portion was specifically reserved for debt reduction.

The proposed issue price of ₹274.10 is effectively at the SEBI pricing floor, not meaningfully above it. A contemporaneous pricing summary reports the 90-day VWAP at ₹261.66 and the 10-day VWAP at ₹274.03; the higher ₹274.03 benchmark determined the floor price under the applicable SEBI ICDR methodology. The issue price is therefore:

• ₹0.07, or approximately 0.03%, above the 10-day VWAP/floor of ₹274.03 ^[3]
• ₹12.44, or approximately 4.8%, above the 90-day VWAP of ₹261.66 ^[3]

This is consistent with the company stating that the ₹274.10 price was above the SEBI-prescribed floor for the 18,24,150-share issue ^[4].

Capital-commitment interpretation

The transaction indicates a shift in the funding channel, but not conclusive evidence that the promoter group has withdrawn financial support.

• The proposed ₹49,99,99,515 issue is being subscribed by Axana Estates LLP and Plutus Investments India Private Limited, rather than through a direct promoter subscription ^[5].
• The previous August 2025 preferential allotment was also an equity raise involving Axana Estates, comprising 20,90,068 shares issued at ₹358.84 per share ^[6]. Therefore, the use of external equity investors is not entirely new.
• Separately, the company has continued to refer to financial support from the promoter group, including promoter funding during the current and prior year ^[6]. A results summary also reports promoter loans of ₹16.19 Cr each being extended for seven years ^[7].

Analyst read: the pattern is better described as externalising the equity-funding requirement while retaining promoter support through loans or other financial assistance, rather than as a clean reduction in promoter commitment. The new issue broadens the non-promoter capital base—adding Plutus alongside Axana—but also causes greater dilution of the promoter percentage on a fully diluted basis, as reported in the revised post-issue shareholding disclosure ^[8]. The proceeds are directed primarily toward clinic expansion, equipment and working capital, rather than debt reduction ^[9].

Important pricing caveat: one extract of Kaya’s pricing certificate reports the minimum issue price as ₹4.03 under Regulation 164 ^[10], which conflicts with the contemporaneous VWAP-based figure of ₹274.03 ^[3]. The ₹274.03 figure is the economically coherent VWAP benchmark, but the filed certificate should be checked to resolve the apparent ₹4.03 versus ₹274.03 inconsistency.